HSCSW

HeartSciences Inc. operates as a medical technology company focused on developing and commercializing artificial intelligence-based cardiovascular diagnostic solutions. Headquartered in Southlake, Texas, the company's flagship product is MyoVista, a non-invasive cardiac diagnostic device that utilizes advanced signal processing and machine learning algorithms to detect cardiac abnormalities. The MyoVista system analyzes electrical signals from the heart to identify conditions such as left ventricular dysfunction and myocardial scarring, providing results in approximately 90 seconds. The device has received FDA 510(k) clearance and CE Mark approval for commercial use in the United States and Europe. HeartSciences targets multiple healthcare settings including cardiology practices, primary care offices, emergency departments, and remote monitoring applications. The company operates under a business model that combines direct sales with strategic partnerships and licensing arrangements to expand market penetration. In recent years, HeartSciences has focused on expanding its commercial infrastructure, pursuing additional clinical validation studies, and exploring applications of its technology for broader cardiovascular screening. The company also holds warrants (HSCSW) that provide investors the right to purchase common stock at a predetermined price, a structure resulting from its business combination that took the company public.